ArticlePloS one2016
In Vitro and In Vivo Antifungal Activity of Lichochalcone-A against Candida albicans Biofilms.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Cardio-green butyl acetate targets ergosterol to killiScience · 2026Article
- Recent Advances in the Synthesis and Biological Applications of Prenylated Chalcones.International journal of molecular sciences · 2025Review
- Identification of prochlorperazine dimaleate as a Sortase A inhibitor from FDA libraries for MRSA infection treatment.RSC advances · 2025Article
- Exploring the Mechanism of CaoHuangGuiXiang Formula in Ameliorating SystemicJournal of inflammation research · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Comparison of herbal products with antifungal drugs in cure of oral candidiasis: A systematic review.Dental research journal · 2025Review
- Article
- Licochalcone A Protects Vaginal Epithelial Cells Against Candida albicans Infection Via the TLR4/NF-κB Signaling Pathway.Journal of microbiology (Seoul, Korea) · 2024Article
- Biochanin A Inhibits the Growth and Biofilm ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Licochalcone A: a review of its pharmacology activities and molecular mechanisms.Frontiers in pharmacology · 2024Review
- Monoterpene antifungal activities: evaluating geraniol, citronellal, and linalool onFrontiers in pharmacology · 2024Article
- Syzygium aromaticum essential oil and its major constituents: Assessment of activity against Candida spp. and toxicity.PloS one · 2024Article
- The potential role of plant secondary metabolites on antifungal and immunomodulatory effect.Applied microbiology and biotechnology · 2023Review
- Novel eco-friendly [1,2,4]triazolo[3,4-a]isoquinoline chalcone derivatives efficiency against fungal deterioration of ancient Egyptian mummy cartonnage, Egypt.Archives of microbiology · 2023Article
- Antifungal and Immunomodulatory Ingredients from Traditional Chinese Medicine.Antibiotics (Basel, Switzerland) · 2022Review
- The Anti-Virulence Effect ofAntibiotics (Basel, Switzerland) · 2022Article
- Pharmacological Effects and Underlying Mechanisms of Licorice-Derived Flavonoids.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- An ethnopharmacological review on the therapeutical properties of flavonoids and their mechanisms of actions: A comprehensive review based on up to date knowledge.Toxicology reports · 2022Review
- Article
- Phloretin inhibited the pathogenicity and virulence factors againstBioengineered · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oral candidiasis (OC) is an opportunistic fungal infection with high prevalence among immunocompromised patients. Candida albicans is the most common fungal pathogen responsible for OC, often manifested in denture stomatitis and oral thrush. Virulence factors, such as biofilms formation and secretion of proteolytic enzymes, are key components in the pathogenicity of C. albicans. Given the limited number of available antifungal therapies and the increase in antifungal resistance, demand the search for new safe and effective antifungal treatments. Lichochalcone-A is a polyphenol natural compound, known for its broad protective activities, as an antimicrobial agent. In this study, we investigated the antifungal activity of lichochalcone-A against C. albicans biofilms both in vitro and in vivo. Lichochalcone-A (625 μM; equivalent to 10x MIC) significantly reduced C. albicans (MYA 2876) biofilm growth compared to the vehicle control group (1% ethanol), as indicated by the reduction in the colony formation unit (CFU)/ml/g of biofilm dry weight. Furthermore, proteolytic enzymatic activities of proteinases and phospholipases, secreted by C. albicans were significantly decreased in the lichochalcone-A treated biofilms. In vivo model utilized longitudinal imaging of OC fungal load using a bioluminescent-engineered C. albicans (SKCa23-ActgLUC) and coelenterazine substrate. Mice treated with lichochalcone-A topical treatments exhibited a significant reduction in total photon flux over 4 and 5 days post-infection. Similarly, ex vivo analysis of tongue samples, showed a significant decrease in CFU/ml/mg in tongue tissue sample of lichochalcone-A treated group, which suggest the potential of lichochalcone-A as a novel antifungal agent for future clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.